We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New AI Blood Test Could Become Game Changer for Bowel Cancer Diagnosis

By LabMedica International staff writers
Posted on 10 Mar 2023
Print article
Image: A fast, inexpensive and scalable test for the early diagnosis of bowel cancer is currently under development (Photo courtesy of Pexels)
Image: A fast, inexpensive and scalable test for the early diagnosis of bowel cancer is currently under development (Photo courtesy of Pexels)

Colorectal cancer (CRC), also referred to as bowel cancer, is the world's third most common cancer and the fourth leading cause of death. It is responsible for approximately 1.4 million new cases and 700,000 deaths every year. In Europe, bowel cancer is the second most prevalent cancer, with 450,000 cases annually. Developed countries have seen an increase in incidence of CRC, and the figures remain high. Early detection of CRC has always been crucial in saving lives. Now, the introduction of a fast, affordable, and scalable test for the early detection of bowel cancer could revolutionize the approach to the diagnosis and screening of this disease.

CanSense Ltd. (Swansea, UK) is harnessing artificial intelligence-based modeling (AI) to create a rapid, affordable, and versatile test that can detect bowel cancer in its early stages, save lives and reduce distress. The test could help dramatically reduce the mortality rate of CRC via early stage diagnosis. It also has the potential to reduce the need for unnecessary invasive colonoscopies and the associated financial burden on healthcare providers.

Negative colonoscopy procedures are associated with considerable economic costs, estimated to be a minimum of USD 4.2 billion worldwide. The blood test can serve as a tool to aid healthcare professionals in determining the necessity of further colonoscopy examinations. From the viewpoint of an anxious symptomatic patient, this approach to CRC triage offers significant advantages. The test can yield quick and accurate results, identifying patients requiring immediate and priority treatment. For those given a negative diagnosis, it effectively eliminates the need for colonoscopy procedures and quickly reduces their anxiety.

Related Links:
CanSense Ltd. 

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Nutating Mixer
Enduro MiniMix
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more